Global Markets for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders

The scope of this study encompasses the neurodegenerative (i.e., progressive ataxia and weakness) disorders in the pharmaceutical and biotechnology markets. The report analyzes each market and its applications, the technologies involved, market projections and market shares. Technological issues include the latest trends and developments. The emerging market for enzyme inhibitors includes India, China, Japan, Canada and Australia. The report informs all market players, potential entrants, government agencies and other interested parties. As the report covers geographic regions in detail, companies interested in expanding geographic reach will also find this helpful.

This report also covers merger and acquisition (M&A) strategies and collaborations, as well as the strengths and weaknesses of each strategy type.

Report Includes

34 data tables and 34 additional tables
A comprehensive overview of the current and future global markets for the treatments of progressive ataxia and weakness disorders
Analyses of the global market trends, with historical market revenue data (sales figures) for 2022, estimates for 2023, forecasts for 2024 and 2026, and projections of compound annual growth rates (CAGRs) through 2028
In-depth information (facts and figures) concerning the major factors influencing the progress of this market (benefits, and industry-specific challenges) with respect to specific growth trends, upcoming technologies, future prospects, and contributions to the overall market
Estimation of the actual market size and revenue forecast for global progressive ataxia and weakness disorders treatments market in USD million values, and corresponding market share analysis based on product, technology, disease type, application, distribution channel, and region
Discussion of the applications for neurodegenerative disorder treatment and therapy technologies, with emphasis on small-molecule and monoclonal antibodies technology
Identification of critical medical and geographical challenges as well as economic and demographic factors affecting the market growth
Review of key patent grants and recent patent applications on neurodegenerative (i.e., progressive ataxia and weakness) disorders in the pharmaceutical and biotechnology markets, along with emerging technologies and new developments
Coverage of recent merger and acquisition (M&A) activities, venture fundings, and other impactful growth strategies in the global market neurodegenerative (i.e., progressive ataxia and weakness) disorders
Identification of the key players operating in the market, and analysis of their competitive landscape based on recent developments, segmental revenues, and operational integration
Company profiles of major players within the industry, including Abbott Laboratories, Glenmark Life Sciences, Novartis AG, Pfizer Inc., Roche Holding Ltd., and Sanofi

Chapter 1 Introduction

Overview
Study Goals and Objectives
Reasons for Doing this Study
Scope of Report
What's New in this Update?
Methodology
Information Sources
Geographic Breakdown

Chapter 2 Summary and Highlights

Market Overview

Chapter 3 Market Overview

Introduction
Definitions
Neurons
Central Nervous System
Brain
Spinal Cord
Neurotransmitters
Classification
Progressive Ataxia and Weakness Disorders
Friedreich's Ataxia
Gertsmann-Straussler-Scheinker Disease
Machado-Joseph Disease/Sca3
Amyotrophic Lateral Sclerosis
Hereditary Spastic Paraplegia
Hereditary Neuropathies
Multiple Sclerosis
Diagnostic Tests for Progressive Ataxia and Weakness Disorders
Diagnostic Tests for Multiple Sclerosis
Diagnostic Tests for Amyotrophic Lateral Sclerosis
Diagnostic Tests for Friedreich's Ataxia
Diagnostic Tests for Machado-Joseph Disease
Diagnostic Tests for Hereditary Spastic Paraplegia
Diagnostic Tests for Hereditary Neuropathies

Chapter 4 Market Dynamics

Introduction
Market Drivers
Progressive Ataxia and Weakness: Increasing Prevalence and Awareness
Technological Advancements and Product Launch
Increasing Expenditures for Health Care
Rise in Alcohol and Drug Use
Market Barriers
Barriers to R&D for Progressive Ataxia
Diagnostic Challenges
Opportunities
Advancements in Research and Technology
Impact of Covid-19, Global Market for Treatment for Syndromes of Progressive Ataxia and Weakness Disorders

Chapter 5 Market Breakdown by Type and Technology

Introduction
Market by Type
Market Overview
Market Revenue
Market by Technology
Market Overview
Market Revenue
Small Molecule
Market Overview
Market Revenue
Monoclonal Antibody
Market Overview
Market Revenue
Others
Biomarkers
Gene Therapy
Stem Cell
Market Overview
Market Revenue

Chapter 6 Market Breakdown by Disease

Overview
Market Revenue
Market by Progressive Ataxia Diseases Type
Friedreich's Ataxia
Market Revenue
Machado-Joseph Disease (Mjd)/Sca3
Market Revenue
Gertsmann-Straussler-Scheinker Disease
Market Revenue
Market by Disease Type
Amyotrophic Lateral Sclerosis
Progressive Bulbar Palsy
Hereditary Spastic Paraplegia
Hereditary Neuropathies (Hns)
Multiple Sclerosis (Ms)

Chapter 7 Market Breakdown by Region

Introduction
North America
The U.S.
Canada
Europe
The UK
Germany
France
Spain
Italy
Russia
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
Rest of Asia-Pacific
Rest of the World

Market Size and Forecast

Chapter 8 Market Breakdown by Distribution Channel

Introduction
Retail Pharmacy
Hospital Pharmacy
Online Pharmacy

Chapter 9 Emerging Technologies and Developments

Introduction
Emerging Technology
Stem Cell Therapy
Gene Therapy
Biomarkers
Nasal Spray for Ms
Disease-Modifying Therapies
Rna-Based Therapies
Conclusion

Chapter 10 Esg Development

Introduction
Esg Investments by Key Players
Consumer Attitudes Towards Esg
Conclusion

Chapter 11 Patent Analysis

Patent Analysis by Year

Chapter 12 M&A and Venture Funding Outlook and Competitive Landscape

Introduction
Mergers, Acquisitions and Collaborations
Strategic Initiatives
Market Shares of Manufacturers of Progressive Ataxia and Weakness Disorders Drugs

Chapter 13 Company Profiles

Abbott Laboratories
Acorda Therapeutics Inc.
American Regent Inc.
Apotex Inc.
Apotheca Inc.
Astellas Pharma Inc.
Astrazeneca GmbH
Baxter International Inc.
Bristol-Myers Squibb
Eisai Co. Ltd.
Eli Lilly and Company
Gilead Sciences Inc.
GlaxoSmithKline plc
Glenmark Life Sciences
Johnson & Johnson
Merck Kgaa
Novartis AG
Pfizer Inc.
Roche Holding Ltd.
Sanofi
Takeda Pharmaceutical Co. Ltd.
Teva Pharmaceutical Industries Ltd.

Chapter 14 Appendix: Abbreviations

List of Tables

Summary Table A: Global Market for Treatments for Syndromes of Progressive Ataxia and Weakness Disorder Drugs, Through 2028
Summary Table B: Global Market for Progressive Ataxia and Weakness Disorders, Through 2028
Table 1: Classification, by Primary Dysfunction
Table 2: Drugs Approved in Europe for Multiple Sclerosis, 2011-2022
Table 3: Global Market for Drug Products for the Treatment of Neurodegenerative Dysfunctions, Through 2028
Table 4: Global Market for Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Technology, Through 2028
Table 5: Global Market for Small Molecule Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Region, Through 2028
Table 6: Global Market for Monoclonal Antibody Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Region, Through 2028
Table 7: Global Market for Other Technology Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Region, Through 2028
Table 8: Global Market for Drug Products for the Treatment of Progressive Ataxia, by Disease Type, Through 2028
Table 9: Global Market for Friedreich’s Ataxia Drugs, by Region, Through 2028
Table 10: Global Market for Machado-Joseph Disease (MJD) Drugs, by Region, Through 2028
Table 11: Global Market for Gerstmann-Straussler-Scheinker (GSS) Drugs, by Region, Through 2028
Table 12: Latest FDA Approvals for Amyotrophic Lateral Sclerosis
Table 13: Drugs in Clinical Trials for ALS, 2022
Table 14: Global Market for Amyotrophic Lateral Sclerosis Drugs, by Region, Through 2028
Table 15: Global Market for Progressive Bulbar Palsy (PBP) Drugs, by Region, Through 2028
Table 16: Global Market for Hereditary Spastic Paraplegia (HSP) Drugs, by Region, Through 2028
Table 17: Global Market for Hereditary Neuropathies Drugs, by Region, Through 2028
Table 18: Latest FDA Approvals for Multiple Sclerosis
Table 19: Global Market for Multiple Sclerosis (MS) Drugs, by Region, Through 2028
Table 20: Global Market for Progressive Ataxia and Weakness Disorders Drugs, by Region, Through 2028
Table 21: North American Market for Progressive Ataxia and Weakness Disorders Drugs, by Country, Through 2028
Table 22: European Market for Progressive Ataxia and Weakness Disorders Drugs, by Country, Through 2028
Table 23: Asia-Pacific Market for Progressive Ataxia and Weakness Disorders Drugs, by Country, Through 2028
Table 24: Global Market for Progressive Ataxia and Weakness Disorders Drugs, by Distributive Channel, Through 2028
Table 25: Global Market for Progressive Ataxia and Weakness Disorders Drugs in Retail Pharmacy, by Region, Through 2028
Table 26: Global Market for Progressive Ataxia and Weakness Disorders Drugs in Hospital Pharmacy, by Region, Through 2028
Table 27: Global Market for Progressive Ataxia and Weakness Disorders Drugs in Online Pharmacy, by Region, Through 2028
Table 28: ESG Ranking of Major Players,2022
Table 29: ESG Investments, by Key Players, 2022
Table 30: ESG Trends, Major Players, 2021
Table 31: ESG Rankings for Major Companies, 2023
Table 32: CDP Scope Card for Major Players, 2022
Table 33: Patent Analysis, by Year, Jan. 2020 to March 2023
Table 34: Major Companies Patents: 2022 to March 2023
Table 35: M&A: Pharmaceutical Companies
Table 36: Abbott Laboratories: Annual Revenue, 2022
Table 37: Abbott Laboratories: News
Table 38: Abbott Laboratories.: Product Portfolio
Table 39: Acorda Therapeutics Inc.: News
Table 40: Acorda Therapeutics Inc.: Product Portfolio
Table 41: Eli Lily and Company: Annual Revenue, 2022
Table 42: Eli Lily and Company: News
Table 43: Eli Lily and Company: Product Portfolio
Table 44: GlaxoSmithKline PLC: Annual Revenue, 2022
Table 45: GlaxoSmithKline PLC: News
Table 46: GlaxoSmithKline PLC: Product Portfolio
Table 47: Glenmark Life Sciences: Annual Revenue, 2022
Table 48: Glenmark Life Sciences: Product Portfolio
Table 49: Novartis AG: Annual Revenue, 2022
Table 50: Novartis AG: News
Table 51: Novartis AG: Product Portfolio
Table 52: Pfizer Inc.: Annual Revenue, 2022
Table 53: Pfizer Inc.: News
Table 54: Pfizer Inc.: Product Portfolio
Table 55: Roche Holding Ltd.: Annual Revenue, 2022
Table 56: Roche Holding Ltd.: News
Table 57: Roche Holding Ltd.: Product Portfolio
Table 58: Sanofi: Annual Revenue, 2022
Table 59: Sanofi: News
Table 60: Sanofi: Product Portfolio
Table 61: Takeda Pharmaceutical Co. Ltd.: Annual Revenue, 2022
Table 62: Takeda Pharmaceutical Co. Ltd.: News
Table 63: Takeda Pharmaceutical Co. Ltd.: Product Portfolio
Table 64: Teva Pharmaceutical Industries LTD.: Annual Revenue, 2022
Table 65: Teva Pharmaceutical Industries LTD.: Product Portfolio
Table 66: Abbreviations

List of Figures

Summary Figure A: Global Market for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Summary Figure B: Global Market for Progressive Ataxia and Weakness Disorders, 2020-2028
Figure 1: Share of Global Health Expenditure Database, 2022
Figure 2: Global Market for Drug Products for the Treatment of Neurodegenerative Dysfunctions, 2020-2028
Figure 3: Global Market Shares of Drug Products for the Treatment of Neurodegenerative Dysfunctions, 2022
Figure 4: Global Market for Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Technology, 2020-2028
Figure 5: Global Market Shares of Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Technology, 2022
Figure 6: Global Market for Small Molecule Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Region, 2020-2028
Figure 7: Global Market for Monoclonal Antibody Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Region, 2020-2028
Figure 8: Global Market for Other Technology Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Region, 2020-2028
Figure 9: Global Market for Drug Products for the Treatment of Progressive Ataxia, by Disease Type, 2020-2028
Figure 10: Global Market Shares of Drug Products for the Treatment of Progressive Ataxia, by Disease Type, 2022
Figure 11: Global Market for Friedreich’s Ataxia Drugs, by Region, 2020-2028
Figure 12: Global Market for Machado-Joseph Disease (MJD) Drugs, by Region, 2020-2028
Figure 13: Global Market for Gerstmann-Straussler-Scheinker (GSS) Drugs, by Region, 2020-2028
Figure 14: Global Market for Amyotrophic Lateral Sclerosis Drugs, by Region, 2020-2028
Figure 15: Global Market for Progressive Bulbar Palsy (PBP) Drugs, by Region, 2020-2028
Figure 16: Global Market for Hereditary Spastic Paraplegia (HSP) Drugs, by Region, 2020-2028
Figure 17: Global Market for Hereditary Neuropathies Drugs, by Region, 2020-2028
Figure 18: Global Market for Multiple Sclerosis (MS) Drugs, by Region, 2020-2028
Figure 19: Global Market for Progressive Ataxia and Weakness Disorders Drugs, by Region, 2020-2028
Figure 20: Global Market Shares of Progressive Ataxia and Weakness Disorders Drugs, by Region, 2022
Figure 21: North American Market for Progressive Ataxia and Weakness Disorders Drugs, by Country, 2020-2028
Figure 22: U.S. Market for Progressive Ataxia and Weakness Disorders Drug, 2020-2028
Figure 23: Canadian Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 24: European Market for Progressive Ataxia and Weakness Disorders Drugs, by Country, 2020-2028
Figure 25: UK Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 26: German Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 27: French Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 28: Spanish Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 29: Italian Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 30: Russian Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 31: Rest of European Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 32: Asia-Pacific Market for Progressive Ataxia and Weakness Disorders Drugs, by Country, 2020-2028
Figure 33: Japanese Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 34: Chinese Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 35: Indian Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 36: Australian Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 37: Rest of Asia-Pacific Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 38: Rest of the World Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 39: Global Market for Progressive Ataxia and Weakness Disorders Drugs, by Distributive Channel, 2020-2028
Figure 40: Global Market for Progressive Ataxia and Weakness Disorders Drugs in Retail Pharmacy, by Region, 2020-2028
Figure 41: Global Market for Progressive Ataxia and Weakness Disorders Drugs in Hospital Pharmacy, by Region, 2020-2028
Figure 42: Global Market for Progressive Ataxia and Weakness Disorders Drugs in Online Pharmacy, by Region, 2020-2028
Figure 43: Benefits of Stem Cell Therapy for the Treatment of Syndrome of Progressive Ataxia and Weakness Disorders
Figure 44: Environmental, Social and Governance Factors in the Pharmaceutical Industry for Syndromes of Progressive Ataxia and Weakness Disorders Market
Figure 45: How A Strong ESG Proposition Benefits Pharmaceutical Business
Figure 46: Share of ESG-Geographical Adoption Level Across All Industries, 2022
Figure 47: Shares of Patents Registered/Approved, by Country, Jan. 2020 to July 2023
Figure 48: Global Progressive Ataxia and Weakness Disorders Drugs Market Shares, by Key Manufacturers, 2022
Figure 49: Abbott Laboratories: Annual Revenue, 2021 and 2022
Figure 50: Abbott Laboratories: Revenue Shares, by Business Unit, 2022
Figure 51: Abbott Laboratories.: Revenue Shares, by Region/Country, 2022
Figure 52: Eli Lily and Company: Annual Revenue, 2021 and 2022
Figure 53: Eli Lily and Company: Revenue Shares, by Business Unit, 2022
Figure 54: Eli Lily and Company: Revenue Shares, by Region/Country, 2022
Figure 55: GlaxoSmithKline PLC: Annual Revenue, 2021 and 2022
Figure 56: GlaxoSmithKline PLC: Revenue Shares, by Business Unit, 2022
Figure 57: GlaxoSmithKline PLC: Revenue Shares, by Region/Country, 2022
Figure 58: Glenmark Life Sciences: Annual Revenue, 2021 and 2022
Figure 59: Glenmark Life Sciences: Revenue Shares, by Business Unit, 2022
Figure 60: Novartis AG: Annual Revenue, 2021 and 2022
Figure 61: Novartis AG: Revenue Shares, by Business Unit, 2022
Figure 62: Novartis AG: Revenue Shares, by Region, 2022
Figure 63: Pfizer Inc.: Annual Revenue, 2021 and 2022
Figure 64: Pfizer Inc.: Revenue Shares, by Business Unit, 2022
Figure 65: Pfizer Inc.: Revenue Shares, by Region/Country, 2022
Figure 66: Roche Holding Ltd.: Annual Revenue, 2021 and 2022
Figure 67: Roche Holding Ltd.: Revenue Shares, by Business Unit, 2022
Figure 68: Roche Holding Ltd.: Revenue Shares, by Region, 2022
Figure 69: Sanofi: Annual Revenue, 2021 and 2022
Figure 70: Sanofi: Revenue Shares, by Business Unit, 2022
Figure 71: Sanofi: Revenue Shares, by Region/Country, 2022
Figure 72: Takeda Pharmaceutical Co. Ltd.: Annual Revenue, 2021 and 2022
Figure 73: Takeda Pharmaceutical Co. Ltd.: Revenue Shares, by Business Unit, 2022
Figure 74: Takeda Pharmaceutical Company Limited: Revenue Shares, by Region/Country, 2022
Figure 75: Teva Pharmaceutical Industries LTD.: Annual Revenue, 2021 and 2022
Figure 76: Teva Pharmaceutical Industries LTD.: Revenue Shares, by Business Unit, 2022
Figure 77: Teva Pharmaceutical Industries LTD.: Revenue Shares, by Region, 2022

Executive Summary

Neurological disorders are surging; this trend is particularly noticeable in syndromes associated with progressive ataxia and weakness disorders, such as Friedreich's ataxia, spinocerebellar ataxia and muscular dystrophy. The necessity for effective treatments has intensified as more individuals are affected by these conditions. Friedreich's ataxia, in particular, stands out as the most common form of hereditary ataxia, originating from genetic factors, impacting at least 1 in every 50,000 individuals. According to the National MS Society, multiple sclerosis (MS) has a considerable presence in the United States, with an estimated one million people living with the condition. Society also reports approximately 25,000 new cases of MS diagnosed annually. As patients and healthcare professionals become more aware of these disorders, there is a growing demand for therapeutic interventions to address the challenges these debilitating conditions pose.

Key players in the global market for treatment for syndromes of progressive ataxia and weakness disorders are focused on authorizations and launches of innovative products to develop the portfolio. The product portfolio has a number of drugs used to treat multiple sclerosis, amyotrophic lateral sclerosis and hereditary neuropathies. These drugs are Kesimpta (ofatumumab), Gilenya, Exforge and Zolgensma (onasemnogene abeparvovec). The FDA approved Skyclarys (omaveloxolone) in Feb. 2023; it is the first treatment for Friedreich’s ataxia, a rare inherited degenerative disease that damages the nervous system, characterized by impaired coordination and walking.

The market has seen strategic collaborations between pharmaceutical and product-development counterparts and thus some impressive candidates may hit the market in two to four years. Penetration is also being made into emerging markets, and more European markets are opening up. The major players in the market are Novartis AG, Pfizer, Sanofi, GlaxoSmithKline, Roche Holding Ltd., Merck & Co., Takeda Pharmaceuticals Ltd. and Abbott Laboratories.

Neurodegenerative diseases are primarily categorized as dementia, movement disorders, progressive ataxias and weaknesses. This report intends to present a detailed analysis of the global syndromes of progressive ataxia syndromes. It studies the drug and therapy markets treating those disorders that bring progressive weakness and affect the brain and spinal cord. This report segments the market based on technology, diseases, region and distributive channel. Based on the technology, the market is segmented into small molecules, monoclonal antibodies and others. Based on diseases, progressive ataxia is segmented as Friedreich ataxia, Machado Joseph disease/SCA3 and Gertsmann Straussler Scheinker diseases, and progressive weakness disorders as multiple sclerosis, hereditary neuropathies, amyotrophic lateral sclerosis, progressive bulbar palsy and hereditary spastic paraplegia. Based on region, the market is segmented as North America, Europe, Asia-Pacific and Rest of the World. The North American market had the highest share, followed by Europe. This leadership role is due to increasing prevalence, rising awareness, early diagnosis, the presence of major players, government initiatives, funding and good healthcare infrastructure.

Companies Mentioned

Abbott Laboratories
Acorda Therapeutics Inc.
American Regent Inc.
Apotex Inc.
Apotheca Inc.
Astellas Pharma Inc.
Astrazeneca GmbH
Baxter International Inc.
Bristol-Myers Squibb
Eisai Co. Ltd.
Eli Lilly and Company
Gilead Sciences Inc.
GlaxoSmithKline plc
Glenmark Life Sciences
Johnson & Johnson
Merck Kgaa
Novartis AG
Pfizer Inc.
Roche Holding Ltd.
Sanofi
Takeda Pharmaceutical Co. Ltd.
Teva Pharmaceutical Industries Ltd.

Table Information

Report Attribute	Details
No. of Pages	180
Published	September 2023
Forecast Period	2023 - 2028
Estimated Market Value ( USD ) in 2023	$ 35.1 Billion
Forecasted Market Value ( USD ) by 2028	$ 57.2 Billion
Compound Annual Growth Rate	10.2%
Regions Covered	Global
No. of Companies Mentioned	22

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€5277EUR$5,500USD£4,397GBP
1 - 5 USER LICENSE PDF	The product is a PDF.	This is a 1-5 user license, allowing up to five users have access to the product.	€6332EUR$6,600USD£5,276GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€7599EUR$7,920USD£6,331GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€9118EUR$9,504USD£7,598GBP

Report Includes

Table of Contents

Executive Summary

Companies Mentioned

Table Information

Related Topics

Related Reports

Friedreich Ataxia - Pipeline Insight, 2024

Spinocerebellar Ataxias - Pipeline Insight, 2024

Episodic Ataxia Treatment Market Report 2024

Spinocerebellar Ataxia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Ataxia Global Market Report 2024